Novartis invests up to $7.8 billion in Chinese mRNA drug for autoimmune diseases

Novartis has signed an agreement with Chinese firm Abogen Biosciences, investing up to $7.8 billion in experimental drug ABO2203. The mRNA-based therapy targets autoimmune diseases by destroying specific B lymphocytes. The deal signals growing importance of Chinese biotech firms as a source of innovation for global pharmaceutical companies.

Similar stories

📈 Business EU trade commissioner travels to Beijing to prevent trade war with China Interia Biznes · 2h ago 📈 Business Japanese firms withdraw from China at record pace CNBC · 6h ago 🔬 Science SMILE mission photographs northern lights in ultraviolet CHIP · 1d ago